DelveInsight’s, “Metastatic-Liver-Cancer Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Metastatic Liver Cancer Treatment Drugs @ Metastatic Liver Cancer Pipeline Outlook
Key Takeaways from the Metastatic Liver Cancer Pipeline Report
- In October 2024: HepaRegeniX GmbH- The goal of this clinical trial is to learn if HRX215 is safe and tolerable in adults who have undergone surgical removal of metastatic tumor(s) due to colorectal carcinoma in the liver.
- In October 2024:- DualityBio Inc.- A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors. This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- DelveInsight’s Metastatic Liver Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Liver Cancer treatment.
- The leading Metastatic Liver Cancer Companies such as Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
- Promising Metastatic Liver Cancer Therapies such as ThermoDox® (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG®-1, AV-299, RO7119929, Tocilizumab, and others.
Find out more about Metastatic Liver Cancer Therapeutics Assessment @ Metastatic Liver Cancer Preclinical and Discovery Stage Products
Metastatic Liver Cancer Emerging Drugs Profile
- exoASO STAT6: Codiak BioSciences
exoASO™-STAT6 is an exosome therapeutic candidate engineered using our engEx™ Platform to overexpress Codiak’s novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
- STP 705: Sirnaomics
STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
- ONCR 177: Oncorus
ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
Explore groundbreaking therapies and clinical trials in the Metastatic Liver Cancer Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Liver Cancer Drugs
Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Metastatic Liver Cancer Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Unveil the future of Metastatic Liver Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Liver Cancer Market Drivers and Barriers
Scope of the Metastatic Liver Cancer Pipeline Report
- Coverage- Global
- Metastatic Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
- Metastatic Liver Cancer Therapies- ThermoDox® (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG®-1, AV-299, RO7119929, Tocilizumab, and others.
Get the latest on Metastatic Liver Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Liver Cancer Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Metastatic-Liver-Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic-Liver-Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name :Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name :Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ONCR 177: Oncorus
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name :Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic-Liver-Cancer Key Companies
- Metastatic-Liver-Cancer Key Products
- Metastatic-Liver-Cancer- Unmet Needs
- Metastatic-Liver-Cancer- Market Drivers and Barriers
- Metastatic-Liver-Cancer- Future Perspectives and Conclusion
- Metastatic-Liver-Cancer Analyst Views
- Metastatic-Liver-Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
